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Summary The cellular distribution of 4-borono-2-["8F]fluoro-L-phenylalanine (['8F]FBPA, an analog of p-
boronophenylaline), a potential agent for boron neutron capture therapy (BNCT), and [6-3H]thymidine
([3H]Thd, a DNA precursor) in murine two B16 melanoma sublines and FM3A mammary carcinoma was
studied in vivo using double-tracer microautoradiography. Tumour volume, tumour age, cell density in the
tissues and the proportion of S phase cells in the cell cycle were the same in the three tumour models. Volume
doubling time, which represents tumour growth rate, was fastest in B16F10, followed by B16F1 (P<0.05), the
slowest being in FM3A (P<0.001). The rate of DNA synthesis in S phase cells corresponded to the volume
doubling time. The greatest amount of ['8F]FBPA was observed in S phase melanocytes and the lowest
amount was found in non-S phase non-melanocytes. The ['8F]FBPA accumulation was primarily related to the
activity of DNA synthesis and, secondarily, to the degree of pigmentation in melanocytes. The therapeutic
efficacy of BNCT with p-boronophenylalanine may be greater in melanoma that exhibits greater DNA
synthesis activity and higher melanin content.
p-Boronophenylalanine (BPA) has been studied as a potential
agent for boron neutron capture therapy (BNCT) for melan-
omas (Mishima et al., 1989a,b). The success of this treatment
is dependent on the highly selective localisation and con-
centration of boron-10 in tumours vs normal tissues. Bio-
distribution studies and radiation dosimetry based on
pharmacokinetics have indicated that BPA acts as a bio-
chemically targeted boron carrier for melanomas in vivo
(Barth et al., 1990; Coderre et al., 1988). Double-labelled
neutron capture radiograms of '°B-L-BPA and [3H]Thd auto-
radiograms from the same whole-body section showed that
high concentration of boron in the tumour corresponded
closely with areas of rapid cell division (Coderre et al., 1987).
However, the relationship of BPA accumulation to DNA
synthesis and pigmentation is still unclear (Tsuji et al., 1983;
Ichihashi et al., 1982; Ishiwata et al., 1992a).
In recent studies carried out to accurately determine the in
vivo concentration of the compound, '8F labelled borono-
phenylalanine (4-borono-2-['8F]fluoro-L-phenylalanine; ['8F]-
FBPA) has been synthesised as a positron emitting tracer
which can be quantified non-invasively in vivo by positron
emission tomography (PET) (Ishiwata et al., 1991a,b;
1992a,b). Chemically determined '0B-BPA concentration in
the Greene's melanomas was comparable to the value esti-
mated with ['8F]FBPA (Ishiwata et al., 1992b). Thus ["8F]-
FBPA showed potential value for non-invasive BNCT dosi-
metry with '0B-BPA.
High selectivity of ['8F]FBPA for B16 melanoma (wild
type) (Ishiwata et al., 1991b) and FM3A tumour (Ishiwata et
al., 1992b) in mice was reported in both whole-body auto-
radiography and tissue distribution study. The tumours
showed 3.2 to 8.1 times higher uptake of ['8F]FBPA than the
normal tissues except pancreas and kidney, of which tracer
distribution pattern is typical for amino acid analogs. The
investigation of the biochemical and physiological mechan-
isms by which the boron compound concentrates in tumours
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is important for assessing the cell biological efficacy of the
compound in BNCT (Barth et al., 1990).
In our previous study (Kubota et al., 1992a), we reported a
double-tracer microautoradiography (micro-ARG) method;
this method allowed the simultaneous investigation of two
distinct metabolic processes in one in vivo experimental
model system at the cellular level. The relationship between
melanogenesis and the proliferation ofmelanoma cells in vivo
was determined by monitoring the accumulation of 3,4-
dihydroxy-2-['8Fjfluoro-L-phenylalanine (2-["8F]FDOPA), an
analog of a melanin synthesis substrate, and by determining
the accumulation of [6-3H]thymidine ([3H]Thd), a DNA pre-
cursor.
In this present study, using this technique, we demonstrate
the relationship between the cellular accumulation of ['8F]-
FBPA, DNA synthesis, in vivo tumour growth rates, and
pigmentation, using in vivo mouse melanoma B16F1 and
B16FIO, and FM3A carcinoma models to elucidate the
kinetics of ['8F]FBPA as an analog and as a marker of
'°B-BPA for successful BNCT.
Materials and methods
The ['8F]FBPA was synthesised by the direct fluorination of
BPA with [18F]AcOF, followed by separation by high-per-
formance liquid chromatography (Ishiwata et al., 1991a,
1992b). The double-tracer experiment and micro-ARG were
performed as described previously in detail (Kubota et al.,
1992a), using ['8F]FBPA instead of 2-['8F]FDOPA. Briefly,
C57BL/6 male mice with subcutaneously transplanted B16F1
and B16FIO tumours, and C3H/He male mice with FM3A
tumours were injected with 1 mCi of ['8F]FBPA and 20ItCi
of [3H]Thd intravenously through the tail vein. The mice
were killed I h later and the tumours were quickly removed
and prepared for frozen sectioning (Yamada et al., 1990).
Under a safety light, frozen 5-.m sections were directly
mounted on slides coated with NTB2 emulsion. After 4 h of
exposure under dry ice cold, the sections were fixed with 5%
acetic acid; the autoradiograms were developed in Konidol-X
(Konica, Japan), fixed in Kodak general purpose fixer
(Kodak, Japan), washed, and dried. Three days after the first
ARG for the complete decay of '8F (t1/2= 109.8 min), the
second ARG was processed with ET2F stripping film. Under
a safety light, the slides with sections and the first auto-
radiogram were covered with ET2F stripping film; the film-
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coated slides were then exposed for 3 weeks. After exposure,
the films were developed, fixed, washed, and dried as describ-
ed above. The specimens were stained with hematoxylin and
eosin. Grain counts were obtained by focusing a transmitted
light brightfield microscope alternately on the upper and
lower emulsion layers, using a micrometer. Non-radioactive
tumour sections were included in each group on a separate
slide as a chemographic control.
The relationship between grain numbers and '8F radio-
activity was determined using liver sections of mice injected
with '8F-tracer at different doses, as uniform step-wise stan-
dards ofradioactive sample (Kubota et al., 1992a,b). A linear
relationship between grain numbers per 100ILm2 (Y) and the
corresponding '8F radioactivity (fCi/100pm2, X) (Y = 0.42
X + 0.35, n = 40, r = 0.9996, P<0.001) has been observed.
This finding supported the validity of the grain counting
method used in this study for the quantification of '8F micro-
ARG. The quantitative characteristics of [3H]Thd micro-ARG
have been studied for 40 years and have been established as a
marker of de novo DNA synthesis (Cory & Whitford, 1972;
Tsuya et al., 1979). Self-absorption, which reduces the frac-
tion of particles from 3H in the specimen that can reach the
emulsion, was considered to be comparable in the three types
of tumour tissues, in which there were no significant differ-
ences in section thickness and cell density, and which were
processed under the same conditions throughout. The back-
ground level was subtracted from the relevant data. Mela-
noma cells were microscopically classified according to the
['8F]FBPA
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degree of pigmentation, as graded by Bennett (1983): unpig-
mented and very lightly pigmented cells were classified as
non-melanocytes, and lightly, moderately, and well-pig-
mented cells were classified as melanocytes. Tumour growth
curves were determined from the products of three principal
diameters of the in vivo tumours (Kubota et al., 1983) grow-
ing under the same conditions in tracer experiments.
The animals used in this study were maintained in the
animal care facility of our institution and the study protocol
was approved by the laboratory animal care and use com-
mittee of Tohoku University.
Results
Figure 1 shows three pairs of double-tracer micro-ARG in
B16FIO, B16F1, and FM3A tumours, which were embedded
in one sample block and processed as a section containing
three tumour tissues. This procedure made it possible to
visually compare the distribution and grain levels of tracers
in the three tumour tissues and the melanin content in both
melanomas. The grains obtained with ['8F]FBPA were
diffusely distributed throughout the area. Some of them
seemed to overlap on melanin in B16FIO and B16FI. The
micro-ARG of B16FO0 had more [18F]FBPA grains than that
of B16FI, while that of FM3A had fewer. B16F1 was more
strongly pigmented than B16FIO. The cells in the S phase of
the cell cycle were labelled with [3H]Thd. Because of differ-
[3H]Thd
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Figure 1 Three pairs of double-tracer micro-ARG with ['8F]FBPA and [3H]Thd. a, B16F1O; b, B16FI; c, FM3A. Left: focused on
the ['8F]FBPA microautoradiogram. Right: focused on the [3H]Thd microautoradiogram. Brown pigments: melanin. Bar 30pm.
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ences in de novo DNA synthesis rates, grain levels in S phase
cells were heterogeneous, with large variations; however, the
number of strongly labelled cells was greater in B16F1O than
B16F1 and less in FM3A.
Figure 2 shows the growth curves of the three tumour
models. The tracer study was performed 11 ± 0.5 days after
transplantation when the tumours grew to the same size in
order to unify the experimental condition of animals.
Table I summarises the profiles of the three tumour
models, [3H]Thd labelling indices and grain levels, and pro-
portions of melanocytes when the tracer study was per-
formed. Tumour volume, cell density in the tissues, and
[3H]Thd labelling indices, which represent the proportion of S
phase cells, were the same in the three models. However,
volume doubling times were significantly shorter in B16F1O
than in B16F1 (P<0.05) and were longest in FM3A (P<
0.001). The number of grains per cell, determined by [3H]Thd
in the S phase cells, was also highest in B16F10 (P< 0.05 to
B16F1) and lowest in FM3A (P<0.001 to B16FIO and
B16F1). A greater rate of DNA synthesis is considered to
induce a faster growth rate when the proportion of S phase
cells in the cell cycle is the same. The proportion of melano-
cytes was significantly higher in B16F1 than in B16F1O
(P<0.001). Figure 1 shows the histological characteristics of
both subcloned melanoma cell lines as well as the differences
of melanin content in melanocytes.
Table II-A shows the results of ['8F]FBPA grain counting
in each group of cells discriminated by [3H]Thd labelling and
pigmentation. All groups of cells showed ['8F]FBPA accumu-
lation. B16F1O showed the greatest accumulation (significant
in all groups except in [3H]Thd-unlabelled melanocytes com-
pared to B16Fl), and FM3A the lowest (P<0.001) among
the three. The highest concentration of ['8F]FBPA was
observed in [3H]Thd-labelled melanocytes, both in B16F1O
and B16F1, followed by [3H]Thd-labelled non-melanocytes
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Figure 2 Male 10-week-old C57BL/6 mice were subcutaneously
injected with a suspension of 2 x 106 B16F1 cells on their left
thighs and that of 1.7 x 106 B16F1O cells on their right thighs.
Male 10-week-old C3H/He mice were subcutaneously injected
with a suspension of 7 x 106 FM3A ascitic cells on their left
thighs. Solid tumours produced on their thighs were measured
with vernier calipers and the product of three principal diameters
of the tumour was designated as 'tumour volume' as described
previously (Kubota et al., 1983). Tumour growth curves were
obtained as the average of data from five C57BL/6 mice and six
C3H/He mice. Day 0 is the day when the tumour cells were
transplanted. Tumour volume of less than 100mm3 was tech-
nically unmeasurable in vivo. The tracer study was performed on
Day 11±0.5.
Table I Profiles oftumour models and results of[3H]Thd microautoradiography
Volume [3H]JThd
Tumour volume doubling Cell density labelling index Melanocytes
Cell line n* (mm3) time (day) n** (cells/JO' pm) (%) grains/cell (%)
B16F10 5 658± 101 1.83±0.48a 11 77.43±7.85 28.13±5.65 174.30±71.1la 23.81± 11.60c
B16FI 5 608±141 2.89±0.58b 21 75.29± 14.16 27.03± 5.18 108.14±42.66b 40.08±8.99
FM3A 6 614±161 4.78±0.68 7 79.17±6.11 26.98±3.02 62.17± 18.78 -
ap<0.05comparedtoB16F1 andP<0.00 comparedtoFM3A.bp<0.001 compared toFM3A.CP<0.001 compared
to Bl6F1. n*: number of animals. Mean±s.d. n**: number of sections. Each value is the mean±s.d. of three to five
tumours. Foreachtumour, two tofivesections wereanalysed; foreach section, fourmicrogridareas(100 x 100pm2each)
were randomly selected and averaged.
Table lI-A Number ofgrains with ['8F]FBPA per cell discriminated by [3H]Thd-labelling and
pigmentation
[3H]Thd-labelled [3H]Thd-unlabelled
Cell line n (section) Melanocytes Non-melanocytes Melanocytes Non-melanocytes
B16F1O 11 10.37±1.92 8.58±2.39 7.05±l.54a 5.48+2.06a,b
B16F1 21 7.37±2.629 5.69+2.37Cg 5.65±2.41c 4.09+1.47a,d,ffh
FM3A 7 - 3.22±0.43' _ 1.99±0.28'i
Mean±s.d. Grain counting was performed on the same areas as those for [3H]Thd grain
counting. ap< 0.001 and cP<0.05 compared to [3H]Thd-labelled melanocytes. bp< 0.005 and
dp<0.05andep<0.001 comparedto[3H]Thd-labelled non-melanocytes. fP<0.05 compared to
[3H]Thd-unlabelled melanocytes. 9P<0.005 and hp<0.05 compared to B16F1O. iP<0.001
compared to B16FI.
Table II-B Differences of grain numbers with ['8F]FBPA in each cell group
Melanocytes-related accumulation DNA synthesis-related accumulation
(Melanocytes)-(Non-melanocytes) ([3H]Thd-labelled)-(['HJThd-unlabelled)
Cell line [3H]Thd-labelled[3H]Thd-unlabelled Melanocytes Non-melanocytes
B16F1O 1.79 1.57 3.32 3.10
B16F1 1.68 1.56 1.72 1.60
FM3A - - - 1.23
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(P<0.05 in B16F1) and [3H]Thd-unlabelled melanocytes
(P<0.001 in B16F10 and P<0.05 in B16F1). The lowest
concentration of ['8F]FBPA was seen in [3H]Thd-unlabelled
non-melanocytes (P<0.001 in both). [3H]Thd-labelled cells
showed greater ['8F]FBPA accumulation than unlabelled cells
in FM3A (P<0.001).
Calculations of melanocyte- and DNA synthesis-related
accumulation of ['8F]FBPA are shown in Table II-B. The
melanocyte-related accumulation of ['8F]FBPA in B16F1 was
comparable to that in B16F1O, whereas the melanin content
in B16F1 was greater than that in B16F1O. Both tumour
models showed smaller increases in S phase than in non-S
phase cells. The DNA synthesis-related accumulation of ['8F]-
FBPA was 1.9 times greater in B16FIO than in B16F1 in
both melanocytes and non-melanocytes, corresponding to 1.6
times greater [3H]Thd grain numbers in B16F10 than in
B16F1 (Table I). Both these tumour models showed smaller
increases in melanocytes than in non-melanocytes. These
observations suggested that the ['8F]FBPA accumulation in
[3H]Thd-unlabelled non-melanocytes/FM3A represented the
basic value, probably, in accordance with the amino acid
transport/demand of the tumour. The increases in ['8F]FBPA
accumulation were probably induced by DNA synthesis and,
also, to some extent, by melanin incorporation.
Discussion
Double-tracer microautoradiography allowed the simultan-
eous investigation of DNA synthesis and ['8F]FBPA accum-
ulation at the cellular level, and suggested that the faster the
growth rate the greater was the DNA synthesis, and greater
DNA synthesis induced higher levels of ['8F]FBPA accumula-
tion. Some studies of cell proliferation kinetics using DNA
flow cytometry, bromodeoxyuridine, and [3H]Thd had dem-
onstrated constancy in the proportion of cells in each cell
cycle phase, while the total cell cycle time was prolonged in
accordance with the age of transplanted tumour (Skog et al.,
1990; Hessels et al., 1991). A slow progression through the
cell cycle was shown to be accompanied by a reduced DNA
synthesis rate (Harada & Morris, 1981; Santavenere et al.,
1991). In this present study, while all three tumour models
showed the same S phase proportion, the DNA synthesis rate
was significantly greater in B16F10. Increased DNA synthesis
has been shown to be accompanied by increased protein
synthesis (Bagby et al., 1992); the increased protein synthesis
rate can be considered to stimulate amino acid transport/
demand. ['8F]FBPA accumulation, as well as BPA accumula-
tion, by the tumour is considered to be dependent on the
amino acid transport system (Tsuji et al., 1983; Coderre et
al., 1988). The transport/demand into the cells is related to
the activity of DNA synthesis; however it appears that the
accumulated ['8F]FBPA does not incorporate into protein
synthesis, as shown by the finding of Ishiwata et al. (1992a)
that ['8F]FBPA was stable to metabolic alteration in FM3A;
no radioactivity was incorporated into proteins and that 89%
of radioactivity was detected as ['8F]FBPA in melanoma.
On the other hand, 11% of radioactivity was detected in
the acid-insoluble fraction in melanomas 1 h after injection of
['8F]FBPA. The incorporation of ['8F]FBPA into melanin
production was suggested but the mechanism remains un-
clear. In our previous study, we demonstrated the relation-
ship between melanogenesis and proliferation of melanoma
cells with 2-['8F]FDOPA, a DOPA analog of a melanin
synthesis substrate, and with [3H]Thd (Kubota et al., 1992a).
We found that melanogenesis was activated only in the non-S
phase melanocytes, and was increased in tissue with higher
melanin content (B16F1 > B16F10).
The accumulation patterns of ["8F]FBPA, which were
obtained by the same analytic technique as that used in the
2-['8F]FDOPA study, were different from those of 2-['8F]-
FDOPA and were primarily related to the DNA synthesis
activity. Poorly pigmented but highly DNA synthesising
B16F1O showed higher ['8F]FBPA accumulation than B16F1;
this observation is consistent with the preliminary results of
Coderre et al. (1987). However, the melanocyte-related
accumulation of ['8F]FBPA in B16FI, which had less DNA
synthesis activity but higher melanin content than B16F10,
was the same as that in B16F1O, regardless of S or non-S
phase cells. It may be reasonable to consider that this
melanocyte-related ['8F]FBPA accumulation, which was
greater in the cells with higher melanin content, was a result
of ['8F]FBPA participation in melanin production.
In conclusion, we consider that two independent mechan-
isms account for [18F]FBPA accumulation in the tumour
cells. The primary one is amino acid transport/demand which
responds to the activity of DNA synthesis, the rate of DNA
synthesis being related to the in vivo tumour growth rate. The
["8F]FBPA accumulated by this mechanism does not incor-
porate into protein synthesis. The second mechanism is mela-
nin incorporation, which is increased with melanin content.
The metabolism is unclear, but the participation in melanin
production is considered. These observations regarding tracer
uptake mechanisms suggest that the therapeutic efficacy of
BNCT using BPA may be higher in melanomas that have
high DNA synthesis activity, therefore high growth rate, and
high melanin content.
We hope this study will aid in the understanding of the
pharmacokinetics of '°B-BPA in melanoma. The relative con-
centration of this compound can be assessed non-invasively
in vivo by PET, using a 18F-labelled tracer; ['8F]FBPA. The
development of positron-labelled boron compounds and the
study of their kinetics may be a new approach for making
progress with BNCT.
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